Clinical Programs

TallClinicalCardiac Arrest Program

  • Cardiac arrest (CA): abrupt loss of heart function, related to electrical system. Often precipitated by heart attack, related to blood flow blockage.
  • Prevalence:
    • 3rd leading cause of death (~1 CA/min in US)
      • ~570,000/yr in US, with 2/3 originating out-of-hospital Only
    • Prognosis:
      • <10% of CA patients survive to discharge
      • 75% of deaths occur from brain injury
      • 75% of survivors return to work
    • Pharmacological Therapy:
      • Therapeutic hypothermia is becoming the standard of care (AHA guidelines)
      • No treatment approved for neuroprotection post-CA
  • Clinical Trials
    • Following positive results from a Phase II out-of-hospital cardiac arrest (OHCA) trial of Xenon versus the standard of care, NP is advancing the program to a pivotal Phase III OHCA trial

Anesthesia-Induced Developmental Toxicity (AIDN) Program

  • Definition: Brain injury resulting in L-T cognitive deficits in infants exposed to general anesthesia Risk for disability in language, cognition, & behavior
  • Prevalence:
    • 1.5M infants ≤1 yr of age receive anesthesia/sedation in US
    • 115K high-risk children < 3 yrs of age undergo in-patient surgery in US
  • Awareness: #1 clinical concern in anesthesia
    • Recent articles in NEJM & JAMA
    • SmartTots (FDA & IARS Partnership)
    • ASA Congressional call to action
  • Preclinical Trials:
    • Xe prevents AIDN in rats, mice, piglets
    • NP is committed to providing resources in support of planned primate studies:
      • FDA’s National Center for Toxicological Research
      • NIH-sponsored Research at Oregon Health Sciences University